arrow
V

Verena Petzer

university clinics of internal medicine v
H指数:25
被引数:2,472

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

30 years in service, 1996–2026: Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

30年服务历程,1996–2026:德国血液学和肿瘤学学会(DGHO)感染性疾病工作组(AGIHO)

2026-08-030
OA
Anti-infective vaccination strategies in patients with haematological malignancies or solid tumours: updated guideline of the Infectious Diseases Working Party of the German Society for Hematology and Medical Oncology

血液病或实体瘤患者的抗感染疫苗接种策略:德国血液学与肿瘤学学会感染性疾病工作组更新指南

2026-03-300
PRE
Ferric Carboxymaltose Increases Fracture Risk in Patients and Reduces Bone Formation in Mice with Iron Deficiency Anemia

蔗糖铁增加缺铁性贫血患者骨折风险,并降低小鼠骨形成

Blood
IF23.1
2026-03-200
OAAI
Underrated, Unvaccinated, Untreated: A Multinational Registry Analysis of Hmpv in Haematological Malignancy, Insights From EpiCOVIDeha/Epiresha Registry

被低估、未接种疫苗、未治疗:一项关于血液系统恶性肿瘤患者Hmpv的多国登记分析,来自EpiCOVIDeha/Epiresha登记研究的见解

2026-02-270
OA
Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

低危骨髓增生异常综合征患者移植适应症的EUMDS登记临床结局:对移植策略的启示

2026-02-010
PRE
Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2-A Report From the EPICOVIDEHA/EPIRESEHA Registry
2025-12-010
OAAI
Efficacy assessment following shortened venetoclax exposure in AML patients treated with venetoclax plus hypomethylating agents: a real-world, multicentric study

缩短维奈克拉暴露后AML患者接受维奈克拉联合去甲基化药物治疗的疗效评估:一项真实世界、多中心研究

2025-10-220
OA
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023-2024: EPICOVIDEHA-EPIFLUEHA Report
2024-12-230
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
A human anti-matriptase-2 antibody limits iron overload, α-globin aggregates, and splenomegaly in β-thalassemic mice
2024-04-115
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Efficacy and safety of tixagevimab/cilgavimab as passive immunisation against COVID-19 infections in patients with hematological malignancies

tixagevimab/cilgavimab作为血液系统恶性肿瘤患者新型冠状病毒肺炎感染的被动免疫的有效性和安全性

2024-03-021
PRE
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

通过新型冠状病毒肺炎大流行,多发性骨髓瘤和SARS-COV-2感染的生存率: epicovideha注册表的结果

2023-12-049
OAAI